company background image
CDTX

Cidara Therapeutics NasdaqCM:CDTX Stock Report

Last Price

US$0.66

Market Cap

US$46.2m

7D

-1.5%

1Y

-60.5%

Updated

15 Aug, 2022

Data

Company Financials +
CDTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

CDTX Stock Overview

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States.

Cidara Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cidara Therapeutics
Historical stock prices
Current Share PriceUS$0.66
52 Week HighUS$2.39
52 Week LowUS$0.40
Beta1.53
1 Month Change-6.58%
3 Month Change36.67%
1 Year Change-60.48%
3 Year Change-55.10%
5 Year Change-90.22%
Change since IPO-95.88%

Recent News & Updates

Aug 09

Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M

Cidara Therapeutics press release (NASDAQ:CDTX): Q2 GAAP EPS of -$0.19 beats by $0.09. Revenue of $6.22M (-81.1% Y/Y) beats by $0.01M.

Shareholder Returns

CDTXUS BiotechsUS Market
7D-1.5%1.4%3.6%
1Y-60.5%-19.6%-9.6%

Return vs Industry: CDTX underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: CDTX underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is CDTX's price volatile compared to industry and market?
CDTX volatility
CDTX Average Weekly Movement14.3%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: CDTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: CDTX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201289Jeff Steinhttps://www.cidara.com

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company’s lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19.

Cidara Therapeutics, Inc. Fundamentals Summary

How do Cidara Therapeutics's earnings and revenue compare to its market cap?
CDTX fundamental statistics
Market CapUS$46.25m
Earnings (TTM)-US$66.29m
Revenue (TTM)US$27.63m

1.7x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CDTX income statement (TTM)
RevenueUS$27.63m
Cost of RevenueUS$74.94m
Gross Profit-US$47.31m
Other ExpensesUS$18.97m
Earnings-US$66.29m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.95
Gross Margin-171.26%
Net Profit Margin-239.94%
Debt/Equity Ratio-4.6%

How did CDTX perform over the long term?

See historical performance and comparison